{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:23:19Z","timestamp":1768443799419,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K08902"],"award-info":[{"award-number":["16K08902"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10637-021-01131-4","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T22:02:37Z","timestamp":1622066557000},"page":"1707-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-7827","authenticated-orcid":false,"given":"Masahide","family":"Fukudo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837\u2013847","journal-title":"Lancet"},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449\u2013456","journal-title":"Lancet"},{"key":"1131_CR3","doi-asserted-by":"crossref","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, \u00d6berg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","DOI":"10.1056\/NEJMoa1009290"},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132","journal-title":"Lancet"},{"key":"1131_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817\u2013824","journal-title":"Lancet"},{"key":"1131_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"1131_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1067\/mcp.2001.112969","volume":"69","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group (2001) Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 69:48\u201356","journal-title":"Clin Pharmacol Ther"},{"key":"1131_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","volume":"26","author":"JM Kovarik","year":"2004","unstructured":"Kovarik JM, Tedesco H, Pascual J, Civati G, Bizot MN, Geissler J, Schmidli H (2004) Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 26:499\u2013505","journal-title":"Ther Drug Monit"},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","volume":"15","author":"DN Franz","year":"2014","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S (2014) Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 15:1513\u20131520","journal-title":"Lancet Oncol"},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83\u201395","journal-title":"Clin Pharmacokinet"},{"key":"1131_CR11","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1023\/A:1011940108365","volume":"15","author":"A Crowe","year":"1998","unstructured":"Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15:1666\u20131672","journal-title":"Pharm Res"},{"key":"1131_CR12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.bcp.2009.02.013","volume":"77","author":"C Chu","year":"2009","unstructured":"Chu C, Abbara C, No\u00ebl-Hudson MS, Thomas-Bourgneuf L, Gonin P, Farinotti R, Bonhomme-Faivre L (2009) Disposition of everolimus in mdr1a-\/1b- mice and after a pre-treatment of lapatinib in Swiss mice. Biochem Pharmacol 77:1629\u20131634","journal-title":"Biochem Pharmacol"},{"key":"1131_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijpharm.2012.05.028","volume":"434","author":"M Minocha","year":"2012","unstructured":"Minocha M, Khurana V, Qin B, Pal D, Mitra AK (2012) Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp1\/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm 434:306\u2013314","journal-title":"Int J Pharm"},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/FTD.0b013e318273c899","volume":"34","author":"F Lemaitre","year":"2012","unstructured":"Lemaitre F, Bezian E, Goldwirt L, Fernandez C, Farinotti R, Varnous S, Urien S, Antignac M (2012) Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit 34:686\u2013694","journal-title":"Ther Drug Monit"},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","volume":"51","author":"DJ Moes","year":"2012","unstructured":"Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ (2012) Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet 51:467\u2013480","journal-title":"Clin Pharmacokinet"},{"key":"1131_CR16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/ctr.12350","volume":"28","author":"KE Schoeppler","year":"2014","unstructured":"Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR (2014) The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant 28:590\u2013597","journal-title":"Clin Transplant"},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1038\/psp.2013.78","volume":"3","author":"DJ Moes","year":"2014","unstructured":"Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, Bemelman FJ, de Fijter JW, Guchelaar HJ (2014) Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharmacol 3:e100","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1131_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/TP.0b013e31820ae4ac","volume":"91","author":"N Picard","year":"2011","unstructured":"Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P (2011) CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 91:652\u2013656","journal-title":"Transplantation"},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","volume":"64","author":"W Schuler","year":"1997","unstructured":"Schuler W, Sedrani R, Cottens S, H\u00e4berlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64:36\u201342","journal-title":"Transplantation"},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X (2020) mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 10:31","journal-title":"Cell Biosci"},{"key":"1131_CR21","first-page":"2887","volume":"9","author":"JM Peralba","year":"2003","unstructured":"Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Gr\u00fcnwald V, Weiss G, Hidalgo M (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887\u20132892","journal-title":"Clin Cancer Res"},{"key":"1131_CR22","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-13-1759","volume":"20","author":"SC Tang","year":"2014","unstructured":"Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, van Vlijmen BJ, Beijnen JH, Schinkel AH (2014) P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clin Cancer Res 20:3133\u20133145","journal-title":"Clin Cancer Res"},{"key":"1131_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ab.2010.04.022","volume":"403","author":"HE Dekter","year":"2010","unstructured":"Dekter HE, Romijn FP, Temmink WP, van Pelt J, de Fijter JW, Smit NP (2010) A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal Biochem 403:79\u201387","journal-title":"Anal Biochem"},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509","journal-title":"J Am Stat Assoc"},{"key":"1131_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jjco\/hyp120","volume":"40","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K (2010) Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40:17\u201323","journal-title":"Jpn J Clin Oncol"},{"key":"1131_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2131\/jts.38.349","volume":"38","author":"M Okubo","year":"2013","unstructured":"Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H (2013) CYP3A4 intron 6\u00a0C > T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 38:349\u2013354","journal-title":"J Toxicol Sci"},{"key":"1131_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/FTD.0000000000000628","volume":"41","author":"S Falkowski","year":"2019","unstructured":"Falkowski S, Woillard JB (2019) Therapeutic drug monitoring of everolimus in oncology: evidences and perspectives. Ther Drug Monit 41:568\u2013574","journal-title":"Ther Drug Monit"},{"key":"1131_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","volume":"121","author":"M Deppenweiler","year":"2017","unstructured":"Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche ML, Tubiana-Mathieu N, Venat-Bouvet L, Marquet P, Woillard JB (2017) Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res 121:138\u2013144","journal-title":"Pharmacol Res"},{"key":"1131_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11523-018-0596-8","volume":"13","author":"AECAB Willemsen","year":"2018","unstructured":"Willemsen AECAB, de Geus-Oei LF, de Boer M, Tol J, Kamm Y, de Jong PC, Jonker MA, Vos AH, Grootjans W, de Groot JWB, Mulder SF, Aarntzen EHJG, Gerritsen WR, van Herpen CML, van Erp NP (2018) Everolimus exposure and early metabolic response as predictors of treatment outcomes in breast cancer patients treated with everolimus and exemestane. Target Oncol 13:641\u2013648","journal-title":"Target Oncol"},{"key":"1131_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-016-3050-6","volume":"78","author":"D de Wit","year":"2016","unstructured":"de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, Guchelaar HJ, van der Hoeven JJ, Links TP, Kapiteijn E, van Erp NP (2016) Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol 78:63\u201371","journal-title":"Cancer Chemother Pharmacol"},{"key":"1131_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-019-00656-2","volume":"14","author":"AECAB Willemsen","year":"2019","unstructured":"Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML (2019) Prospective study of drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus plus exemestane. Target Oncol 14:441\u2013451","journal-title":"Target Oncol"},{"key":"1131_CR32","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/ijc.29887","volume":"138","author":"AE Willemsen","year":"2016","unstructured":"Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J (2016) mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int J Cancer 138:2312\u20132321","journal-title":"Int J Cancer"},{"key":"1131_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","volume":"22","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Hartmann S, Figueiredo J, Rordorf C, Golor G, Lison A, Budde K, Neumayer HH (2002) Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 22:154\u2013159","journal-title":"Pharmacotherapy"},{"key":"1131_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00007890-200007270-00017","volume":"70","author":"L Kung","year":"2000","unstructured":"Kung L, Halloran PF (2000) Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 70:327\u2013335","journal-title":"Transplantation"},{"key":"1131_CR35","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603\u20131610","journal-title":"J Clin Oncol"},{"key":"1131_CR36","doi-asserted-by":"publisher","first-page":"e28787","DOI":"10.1002\/pbc.28787","volume":"68","author":"KD Wright","year":"2021","unstructured":"Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW (2021) A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer 68:e28787","journal-title":"Pediatr Blood Cancer"},{"key":"1131_CR37","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473\u20131482","journal-title":"Lancet Oncol"},{"key":"1131_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/bcr2930","volume":"13","author":"J White","year":"2011","unstructured":"White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219","journal-title":"Breast Cancer Res"},{"key":"1131_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1634\/theoncologist.2019-0602","volume":"25","author":"M Sharma","year":"2020","unstructured":"Sharma M, Duan Z, Zhao H, Giordano SH, Chavez-MacGregor M (2020) Real-world patterns of everolimus use in patients with metastatic breast cancer. Oncologist 25:937\u2013942","journal-title":"Oncologist"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01131-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:11:39Z","timestamp":1678511499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01131-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01131-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the institutional ethics committee of Asahikawa Medical University (#14085). The study was performed in accordance with the Declaration of Helsinki and its amendments. Written informed consent was obtained from each patient prior to participation in the study.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was approved by the institutional ethics committee of Asahikawa Medical University (#14085). The study was performed in accordance with the Declaration of Helsinki and its amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Written informed consent was obtained from each patient prior to enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}